ClinicalTrials.gg
CompletedNCT05511038VISION-AFUpdated Sep 4, 2025Results posted

A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema

A Phase 4 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Diabetic Macular Edema, sponsored by Bayer. Completed at 10 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
18th of 53
100 · median 49
Started
2022
the only one that year
Phase 4
26 of 53
none open now
Registered
47th of 53
by date
Lead sponsor
9 of 53
Bayer

Among the 53 studies testing aflibercept in Macular Edema, this one is the 18th largest by enrollment, is the only one that started in 2022, is one of 26 in phase 4, and was the 47th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people who have diabetic macular edema (DME).

Diabetic macular edema (DME) is a complication of diabetes. Consistently high blood sugar due to poor glucose control over time can damage small blood vessels in the body, including the eye. Damaged blood vessels in the eye may lead to leakage of the fluid into the central part of the retina at the back of the eye (also called macula) where sharp, straight-ahead vision occurs. Fluid accumulation makes the macula swell and results in reduced vision. If not treated, DME can result in complete loss of central detailed vision.

The study treatment intravitreal aflibercept (also called BAY865321) works by blocking VEGFR-1 receptor activity. Intravitreal aflibercept is already approved in over 105 countries for doctors to prescribe to people with DME. In India, aflibercept is approved conditionally for people with DME. The reason for this is that the sponsor was asked to collect more safety data for intravitreal aflibercept in Indian people with DME.

The main purpose of this study is to collect more data to learn how safe intravitreal aflibercept is in Indian people with DME. To see how safe intravitreal aflibercept is, the researchers will collect the information/data on the medical problems the participants may have during the study, and which may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AEs). AEs will be categorized according to relatedness, seriousness, discontinuation of therapy, action taken and outcome.

The study participants will receive aflibercept as an injection directly into the space in the back of the eye once every 4 weeks in the first 5 months, followed by one injection every 8 weeks for the rest of the study duration. Only one eye per participant to be treated with aflibercept will be considered for the study.

Each participant will be in the study for approximately 52 weeks. The treatment duration will be 48 weeks. For each participant 11 visits to the study site are planned. The study team will perform additional safety calls 16 to 36 hours after each visit starting at visit 2. Alternatively, an additional safety visit can be arranged/planned for the day after treatment.

During the study, the study team will:

  • take blood and urine samples
  • examine the participants' eyes
  • do physical examinations
  • examine heart health using ECG
  • check vital signs
  • ask the participants questions about how they are feeling and what adverse events they are having.
  • in- administer the study drug

At the end of the study the participants will be switched to commercially available treatment if recommended by the study doctor/if the participant still benefits from the treatment.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male adult participant ≥18 years of age, with type 1 or 2 diabetes mellitus.
  • Participant must have diabetic macular edema (DME) secondary to diabetes mellitus, involving the centre of the macula (defined as the area of the centre subfield of optical coherence tomography (OCT)) in the study eye.
  • Decrease in vision, determined to be primarily the result of DME in the study eye.
  • Retinal thickness of ≥300 µm in the study eye, as assessed by OCT.
  • Best Corrected Visual Acuity (BCVA) Early Treatment Diabetic Retinopathy Study ( ETDRS) letter score of 73 to 24 (i.e., VA of 20/50 to 20/320) or equivalent in the study eye.
  • Participant for whom the decision to initiate treatment with Intravitreal (IVT) aflibercept has been made by the treating Investigator/Physician.
  • Willing and able to comply with clinic visits and study-related procedures.
  • Provide a signed Form (ICF) prior to any study procedures.

Exclusion criteria

Exclusion Criteria:

  • Having any to the use of IVT aflibercept as listed in the local prescribing information (i.e., ocular or periocular infection, active severe intraocular inflammation, and known to aflibercept or to any of the ).
  • History of vitreoretinal surgery and/or scleral buckling in the study eye.
  • Ocular conditions with a poorer prognosis in the fellow eye than in the study eye.
  • Received previous/ prior treatment as mentioned below:

    • Received anti-Vascular Endothelial Growth Factor (VEGF) drugs in the study eye (pegaptanib sodium, bevacizumab, ranibizumab, etc., including aflibercept) within the last 3 months of Day 1.
    • Received IVT dexamethasone or triamcinolone in the study eye within the last 3 months of Day 1.
    • Received intraocular or periocular in the study eye within the last 4 months of Day 1.
    • Had fluocinolone implant in the study eye within the last 3 years of Day 1.
    • Had dexamethasone implant in the study eye within the last 6 months of Day 1.
    • systemic anti-angiogenic agents within 6 months of Day 1.
  • Uncontrolled glaucoma in the study eye (patient who has had filtration surgery in the past, or likely to need filtration surgery in the future).
  • Only 1 functional eye even if that eye is otherwise eligible for the study.
  • Participated in an study within 30 days prior to screening visit that involved treatment with any drug (excluding vitamins and minerals) or device.
  • Pregnant or breast-feeding women.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Aflibercept

    Participants will receive one aflibercept injection per month (every four weeks) for five consecutive doses, followed by one injection every alternate month (every 8 weeks) for rest of the duration

    Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Interventions

06

What researchers measure

Primary outcomes

  1. Frequency (Number) of Ocular and Non-ocular Treatment Emergent Adverse Events (TEAE).

    Time frame: An AE arising or worsening after the start of study treatment administration until 30 days after the last administration of study treatment, up to 52 weeks.

Secondary outcomes

  1. The Change in BCVA From Baseline to Week 52, as Assessed Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart or Equivalent.

    Proportion of eyes that lose ≥ 5, 10 and 15 ETDRS letters from baseline to Week 52, Overall

    Time frame: From baseline to week 52

  2. Change in Central Retinal Thickness (CRT) From Baseline to Week 52 as Measured by Optical Coherence Tomography (OCT), FA

    Time frame: From baseline to week 52

  3. Proportion of Eyes That Gained ≥ 5, 10 and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters From Baseline to Week 52

    Only 1 eye per patient was enrolled in the study. Therefore, number of participants equals to number of eyes.

    Time frame: From baseline to Week 52

  4. Proportion of Eyes With a ≥2 Step Improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) Score

    Only 1 eye per patient was enrolled in the study. Therefore, number of participants equals to number of eyes. The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) is a standardized tool used to measure the severity of diabetic retinopathy. The scale assesses the level of retinal damage and provides a score based on the presence of specific lesions and the extent of retinal involvement. Scale Range: * Minimum score: 10 (indicating no retinopathy) * Maximum score: 85 (indicating severe retinopathy) Interpretation of Scores: Higher scores indicate worse outcomes, reflecting more severe diabetic retinopathy

    Time frame: From baseline to Week 52

07

Results

Posted Sep 4, 2025

Participant flow

The trial was planned to be conducted at approximately 10-15 study sites across India. A total of 100 patients were enrolled into the study. The study duration was up to 13 months covering 11 visits.

Overall
Participant flow — Overall
MilestoneNaïvePre-Treated
Started10516
Completed7312
Not completed324
Withdrew: Withdrawal by subject53
Withdrew: Screen failure201
Withdrew: Physician decision30
Withdrew: Lost to follow-up30
Withdrew: Death10
Screening
Participant flow — Screening
MilestoneNaïvePre-Treated
Started10516
Completed9916
Not completed60
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow up (1 participant)10
Withdrew: Screen failure30
Withdrew: Screen failure that was identified after screening (1 participant)10
Treatment
Participant flow — Treatment
MilestoneNaïvePre-Treated
Started8515
Completed6811
Not completed174
Withdrew: Withdrawal by subject53
Withdrew: Physician decision40
Withdrew: Lost to follow-up20
Withdrew: Death10
Withdrew: Subject did nod visit the site despite multiple follow-up31
Withdrew: Refuse by subject10
Withdrew: Subject did not go to the site for visit10

Outcome measures

PrimaryFrequency (Number) of Ocular and Non-ocular Treatment Emergent Adverse Events (TEAE).
Time frame:
An AE arising or worsening after the start of study treatment administration until 30 days after the last administration of study treatment, up to 52 weeks.
Reported as:
Number · Percentage of participants
Frequency (Number) of Ocular and Non-ocular Treatment Emergent Adverse Events (TEAE).
Percentage of participantsNaïvePre-TreatedTotal
Ocular36.5 (26.29 to 47.62)60 (32.29 to 83.66)40 (30.33 to 50.28)
Non-Ocular21.2 (13.06 to 31.39)33.3 (11.82 to 61.62)23 (15.17 to 32.49)
SecondaryThe Change in BCVA From Baseline to Week 52, as Assessed Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart or Equivalent.

Proportion of eyes that lose ≥ 5, 10 and 15 ETDRS letters from baseline to Week 52, Overall

Time frame:
From baseline to week 52
Reported as:
Number · Percentage of eyes
The Change in BCVA From Baseline to Week 52, as Assessed Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart or Equivalent.
Percentage of eyesNaïvePre-TreatedTotal
≥ 5 ETDRS letters2.4 (0.3 to 8.2)7.1 (0.2 to 33.9)3 (0.6 to 8.6)
≥ 10 ETDRS letters2.4 (0.3 to 8.2)0 (0.0 to 23.2)2 (0.2 to 7.1)
≥ 15 ETDRS letters2.4 (0.3 to 8.2)0 (0.0 to 23.2)2 (0.2 to 7.1)
SecondaryChange in Central Retinal Thickness (CRT) From Baseline to Week 52 as Measured by Optical Coherence Tomography (OCT), FA
Time frame:
From baseline to week 52
Reported as:
Mean · um
Change in Central Retinal Thickness (CRT) From Baseline to Week 52 as Measured by Optical Coherence Tomography (OCT), FA
umNaïvePre-TreatedTotal
Change in Central Retinal Thickness (CRT) From Baseline to Week 52 as Measured by Optical Coherence Tomography (OCT), FA-203.5 ± 148.19-160.3 ± 127.42-197.4 ± 145.63
SecondaryProportion of Eyes That Gained ≥ 5, 10 and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters From Baseline to Week 52

Only 1 eye per patient was enrolled in the study. Therefore, number of participants equals to number of eyes.

Time frame:
From baseline to Week 52
Reported as:
Count of participants · Participants
Proportion of Eyes That Gained ≥ 5, 10 and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters From Baseline to Week 52
ParticipantsNaïvePre-TreatedTotal
≥5 ETDRS letters761187
≥10 ETDRS letters631174
≥15 ETDRS letters43750
SecondaryProportion of Eyes With a ≥2 Step Improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) Score

Only 1 eye per patient was enrolled in the study. Therefore, number of participants equals to number of eyes. The Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) is a standardized tool used to measure the severity of diabetic retinopathy. The scale assesses the level of retinal damage and provides a score based on the presence of specific lesions and the extent of retinal involvement. Scale Range: * Minimum score: 10 (indicating no retinopathy) * Maximum score: 85 (indicating severe retinopathy) Interpretation of Scores: Higher scores indicate worse outcomes, reflecting more severe diabetic retinopathy

Time frame:
From baseline to Week 52
Reported as:
Count of participants · Participants
Proportion of Eyes With a ≥2 Step Improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) Score
ParticipantsNaïvePre-TreatedTotal
Proportion of Eyes With a ≥2 Step Improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) Score12315

Adverse events

Collected over An AE arising or worsening after the start of study treatment administration until 30 days after the last administration of study treatment, up to 52 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pre-treated0/15 (0%)0/15 (0%)11/15 (73.3%)
Drug Naive1/85 (1.2%)4/85 (4.7%)42/85 (49.4%)
Pre-treated (Ocular)0/15 (0%)0/15 (0%)9/15 (60%)
Drug Naive (Ocular)1/85 (1.2%)0/85 (0%)31/85 (36.5%)
Pre-treated (Non-ocular)0/15 (0%)0/15 (0%)5/15 (33.3%)
Drug Naive (Non-ocular)1/85 (1.2%)4/85 (4.7%)17/85 (20%)
Pre-treated (Study Eye)0/15 (0%)0/15 (0%)7/15 (46.7%)
Drug Naive (Study Eye)1/85 (1.2%)0/85 (0%)12/85 (14.1%)
Pre-treated (Fellow Eye)0/15 (0%)0/15 (0%)3/15 (20%)
Drug Naive (Fellow Eye)1/85 (1.2%)0/85 (0%)22/85 (25.9%)
Most frequent serious events
Most frequent serious events
EventPre-treatedDrug NaivePre-treated (Ocular)Drug Naive (Ocular)Pre-treated (Non-ocular)Drug Naive (Non-ocular)Pre-treated (Study Eye)Drug Naive (Study Eye)Pre-treated (Fellow Eye)Drug Naive (Fellow Eye)
Acute coronary syndromeCardiac disorders0/152/850/150/850/152/850/150/850/150/85
Abdominal discomfortGastrointestinal disorders0/151/850/150/850/151/850/150/850/150/85
Abdominal distensionGastrointestinal disorders0/151/850/150/850/151/850/150/850/150/85
NauseaGastrointestinal disorders0/151/850/150/850/151/850/150/850/150/85
Cerebrovascular accidentNervous system disorders0/151/850/150/850/151/850/150/850/150/85
Breast conserving surgerySurgical and medical procedures0/151/850/150/850/151/850/150/850/150/85
Most frequent other events
Showing 10 of 35
Most frequent other events
EventPre-treatedDrug NaivePre-treated (Ocular)Drug Naive (Ocular)Pre-treated (Non-ocular)Drug Naive (Non-ocular)Pre-treated (Study Eye)Drug Naive (Study Eye)Pre-treated (Fellow Eye)Drug Naive (Fellow Eye)
Conjunctival haemorrhageEye disorders2/151/852/151/850/150/852/151/850/150/85
Macular oedemaEye disorders2/159/852/159/850/150/851/152/851/157/85
Macular thickeningEye disorders2/156/852/156/850/150/851/153/851/153/85
Diabetic retinopathyEye disorders1/152/851/152/850/150/850/150/851/152/85
Visual acuity reducedEye disorders1/154/851/154/850/150/851/152/850/152/85
Vitreous haemorrhageEye disorders1/152/851/152/850/150/851/150/850/152/85
Epiretinal membraneEye disorders1/150/851/150/850/150/851/150/850/150/85
Abdominal painGastrointestinal disorders1/150/850/150/851/150/850/150/850/150/85
PyrexiaGeneral disorders1/152/850/150/851/152/850/150/850/150/85
Febrile infectionInfections and infestations1/151/850/150/851/151/850/150/850/150/85

Baseline characteristics

Safety Analysis Set (SAF): This population included all patients who received at least one dose of the study intervention. The analyses were performed on incident TEAE. An overview table provided overall incidences for patients with any TEAE, any study drug related TEAE, any serious TEAE, any serious study drug related TEAE, any TEAE leading to change of treatment regimen with aflibercept, any TEAE leading to discontinuation of aflibercept, any TEAE with outcome death.

Age, Continuous
Age, Continuous(Years)NaïvePre-TreatedTotal
Mean57.6 ± 9.1159.4 ± 9.0157.9 ± 9.07
Sex: Female, Male
Sex: Female, Male(Participants)NaïvePre-TreatedTotal
Sex — Female41445
Sex — Male441155
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NaïvePre-TreatedTotal
Race — American Indian or Alaska Native000
Race — Asian8515100
Race — Native Hawaiian or Other Pacific Islander000
Race — Black or African American000
Race — White000
Race — More than one race000
Race — Unknown or Not Reported000
Weight (kg)
Weight (kg)(kilograms (kg))NaïvePre-TreatedTotal
Mean64.8 ± 11.3862.4 ± 11.1264.5 ± 11.31
Height (cm)
Height (cm)(Centimeters (cm))NaïvePre-TreatedTotal
Mean161.7 ± 9.18163.3 ± 8.83162.0 ± 9.11
Body mass Index (kg/m2)
Body mass Index (kg/m2)(Kilograms per meter squared (kg/m2))NaïvePre-TreatedTotal
Mean24.7 ± 3.6323.3 ± 2.9924.5 ± 3.57
Number of patients with at least one medical history finding
Number of patients with at least one medical history finding(Participants)NaïvePre-TreatedTotal
Diabetic retinal oedema831598
Cataract8311
Type 2 diabetes mellitus8515100
Hypertension491160
08

Study locations

10 sites
  • L.V. Prasad Eye Institute
    Hyderabad, Andhra Pradesh 500034, India
  • M & J Western Regional Institute of Ophthalmology
    Ahmedabad, Gujarat 380016, India
  • Raghudeep Eye Hospital
    Ahmedabad, Gujarat 380052, India
  • Narayana Nethralaya
    Bengaluru, Karnataka 560010, India
  • Sankara Eye Hospital
    Bengaluru, Karnataka 560037, India
  • Dr. R.P. Centre for Ophthalmic Sciences, AIIMS
    New Delhi, National Capital Territory of Delhi 110029, India
  • Medical Research Foundation, Sankara Nethralaya
    Chennai, Tamil Nadu 600006, India
  • Lotus Eye Hospital and Institute
    Coimbatore, Tamil Nadu 641014, India
  • Disha Eye Hospitals
    Kolkata, West Bengal 700120, India
  • Post Graduate Institute of Medical Education and Research
    Chandigarh, 160012, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Apr 2024, 19 months.

Results were first posted in Sep 2025, 1 year 4 months after primary completion.

Of 63 phase 4 interventional studies under Macular Edema, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2022
First posted
Aug 22, 2022
StartActual
Aug 26, 2022
Primary completionActual
Apr 16, 2024
CompletionActual
Apr 16, 2024
Results first posted
Sep 4, 2025
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05511038
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Aug 22, 2022
Start date
Aug 26, 2022
Primary completion
Apr 16, 2024
Completion
Apr 16, 2024
Results posted
Sep 4, 2025
Last update
Sep 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion